IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $747.00 Consensus Price Target from Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have received an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $747.00.

IDXX has been the subject of several recent analyst reports. UBS Group lifted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays decreased their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th.

IDEXX Laboratories Trading Up 1.3%

IDEXX Laboratories stock opened at $553.32 on Friday. IDEXX Laboratories has a 12 month low of $518.55 and a 12 month high of $769.98. The company has a market capitalization of $43.59 billion, a price-to-earnings ratio of 38.91, a price-to-earnings-growth ratio of 2.94 and a beta of 1.54. The business’s fifty day simple moving average is $560.23 and its two-hundred day simple moving average is $578.70. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company’s revenue was up 9.7% on a year-over-year basis. During the same period last year, the company earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts predict that IDEXX Laboratories will post 14.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IDEXX Laboratories

Several large investors have recently bought and sold shares of the business. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the 2nd quarter valued at about $25,000. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth approximately $26,000. Elevation Wealth Partners LLC grew its stake in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the period. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $26,000. Finally, WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $30,000. 87.84% of the stock is currently owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.